KMT2A and acute myeloid leukemia: Drug administration commenced 6 days after the transplantation of primary AML mouse-derived cells, coinciding with the appearance of GFP+ (MLL-AF9+) cells in the PB of the recipients, as shown in the schedule (Fig. 5A).